HGH vs HMG
FDA Approved vs Extensively Studied
monitor Mechanism-based · 60% Both HGH and HMG can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
HGH HMG
Weight 22,124 Da —
Half-life 3-4 hours (SC), 20-30 minutes (IV) ~32 hours (FSH component: 39-54 hours)
Chain 191 amino acids —
Type Single-chain polypeptide with two disulfide bridges Gonadotropin mixture
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
HMG
01 FDA-approved for fertility treatment
02 Stimulates ovarian follicle development
03 Contains both FSH and LH naturally
04 Promotes spermatogenesis in men
05 Cost-effective alternative to recombinant FSH
06 LH activity may improve fertilization rates
07 Long clinical track record
08 Lower OHSS incidence with HP-hMG
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
HMG
75-150 IU for ovulation induction; 150-300 IU for IVF / Daily during stimulation phase (7-12 days)
Ovulation induction 75-150 IU Daily
IVF stimulation 150-300 IU Daily for 7-12 days
Male fertility 75-150 IU 2-3x weekly
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
HMG
Injection site reactions
Abdominal discomfort
Ovarian enlargement
Mood changes
Headache
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Primary ovarian failure
Uncontrolled thyroid or adrenal dysfunction
Sex hormone-dependent tumors
Abnormal uterine bleeding of unknown cause
Ovarian cysts (not due to PCOS)
Pregnancy
Research Evidence
HGH HMG
Status FDA Approved Extensively Studied
References 4 studies 4 studies
Latest 2024 —
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.